en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">To evaluate the diagnostic potential of joint testing of serum tumor markers containing cytokeratin fragment antigen 21-1 (CYFRA21-1), progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA) as well as neuron-specific enolase (NSE) in a variety oflung cancer (LC). </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The LC group comprised 150 LC patients who were diagnosed for the first time and were not treated. During the same period, 120 patients harbored benign lung diseases and 120 healthy subjects were respectively designated as the benign group and control group. Immunochemiluminescence assay was implemented to detect tumor markers in serum from three groups and different types of LC. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Levels of four serum tumor markers in LC group were elevated relative to control group. CYFRA21-1 level in lung squamous cell carcinoma (LSCC) group was elevated compared to lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) groups. ProGRP and NSE levels in SCLC group increased compared to LSCC and LUAD groups. CEA level in LUAD group was higher compared to LSCC and SCLC groups. The highest positive rate of LSCC was CYFRA21-1, the highest positive rate of LUAD was CEA and the highest positive rates of SCLC were ProGRP and NSE. In terms of single tumor marker detection, CYFRA21-1 possessed the best diagnostic efficiency for LSCC, CEA possessed the best diagnostic efficiency for LUAD, NSE and ProGRP possessed the best diagnostic efficiency for SCLC, respectively. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The individual determination of CYFRA21-1, ProGRP, CEA, and NSE has certain clinical application value for the pathological classification of LC.</span></span></span></span></span></span></span></span></span></div> Lung cancer, tumor markers, diagnosis. 315 319 http://ijrr.com/browse.php?a_code=A-10-1-1176&slc_lang=en&sid=1 W. Liu 7900319475328460026888 7900319475328460026888 No Department of Clinical Laboratory, Beijing Hospital of Integrated Chinese & Western Medicine, Beijing 100039, China D. Zang lww16032810@163.com 7900319475328460026889 7900319475328460026889 Yes Department of Clinical Laboratory, Beijing Hospital of Integrated Chinese & Western Medicine, Beijing 100039, China